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Smoking 
in the 21st century 
INTRODUCTION 
Jean Nicot de Vil lemain (1530 - 1600) 
was a French diplomat who became 
famous for introducing tobacco to 
France. Li ttle could he imagine the 
immense upheaval he would b ring to 
futu re generations. Up unti l the early 
1900's, smoking cigarettes was made 
to look glamorous and even had 
health benefits attri buted to it. 
However, the link between 
smoking and respiratory 
d iseases had been established 
back in the early 1900s in 
studies by European and 
American doctors but th is 
re mained a taboo up until 
the 1950s.1 As time went 
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by, the evidence linking smoking as the caus·e of 
d isease continued to accumulate and, what was a 
controversy in the 1960s arnd 1970s, turned into 
outright condemnation in the 1980s. Although the 
medical profession had more knowledge about the 
harm caused by smoking, the general public was less 
informed !because cigarette manufacturers were doing 
their best to cast doubt on how true these "a llegations" 
were. Mass legal action instituted in the 1991()s led 
to the Master Settlement Agreement in 1998 with \JS 
courts condemning major US cigarette companies to 
pay huge sums of money to the US government over 
a period of 25 years to compensate for some of the 
damage and expenses incurred in caring for the mi llions 
of people suffering ill health directly caused by smoking 
over the years.2 
Over the past couple of decades, regulations 
to control tobacco use have fa llen short of outright 
prohibition. With current knowledge of the harm 
caused by smoking, this would be a sensible thing to 
do. But experience has taught us that prohibition, while 
reducing use of a substance in the general population, 
does not really stop those who are intent on using the 
prohibited substance from doing so.3.4 Legislation to 
control tobacco use aims at reducing harm to smokers 
a nd protect non-smokers from exposure to exhaled 
secondary smoke. It is surprising that, the Manufacture, 
Presentation and Sale of Tobacco and Related Products 
Regulations (S.L. 315.10), enacted under the Tobacco 
(Smoking Control) Act (Cap. 315), actually identifies 
the addictive properties of nicotine and defines 
"addictiveness as the pharmacological potential of a 
substance to cause addiction", which is described as "a 
state which affects an individual's ability to control his or 
her behaviour, typically by instilling a reward or a rel ief 
from withdrawal symptoms, or both." By 2016, Maltese 
legislatiorn with regards to smoking control was updated 
to reflect EU law. The law sipecifies measures to control 
not only concentration of nicotine in cigarettes but, 
probably of more importance, the law describes which 
cancerogenic substances aire a llowed. Surprisingly, the 
law permits use of chemicals that are known to make the 
smoker sick and possibly sick enough to die! Keeping 
up with the t imes, the same legislation S.L. 315.10 
confirms that smokeless tobacco is illegal in Malta and 
also defines and describes electronic cigarettes. 
This brings me to the subject of smoking other 
than conventional cigarettes. Probably most people 
assume thiat smoking is the act of putting a tobacco· 
filled cigarette to one's mouth and lighting it up. The 
process of burning tobacco reaches a temperature as 
high as 650°C where chemicals that are known to be 
cancerogenic tend to be more harmful to the lung tissue 
0f the smoker. However, tobacco can also be smoked 
.rithout burning (combusted or heat-not-burn/HNB) 
&y using a battery-operated device to power a heating 
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element, which when in contact with tobacco; heats 
rather than bums the tobacco. This mode of nicotine 
de livery system (the polite way to refer to smoking) 
heats up tobacco to a temperature of 300 to.350°C, 
generating a vapour that is inhaled by the smoker. At 
the lower temperature, the cancerogenic chemicals in 
tobacco are thought to be less harmful to the smoker. 
The latest fad in smoking is the use of what are 
known as e lectronic cigarettes. Like combusted 
cigarettes, e lectronic cigarettes a re battery-operated 
but instead of heating tobacco, a solution is heated to 
generate a vapour inhaled by the smoker. This is referred 
to as vaping. 
Appearing on the market towards the end of the 20'h 
century, the first electronic cigarettes were patented 
in 2003 and appeared in China in 2004, in Europe 
two years late r and the US in 2007. The prevalenc·e of 
electronic cigarettes in the general population is .3.5 
to 5.5%, but prevalence studies indicate it is a fad t hat 
has mostly engaged young people and adolescents. 
Some US studies indicate rates as high as 46% in th is 
cohort. Most people who use electronic cigarettes also 
smoke conventional cigarettes at some stage during 
their smoking career. Studies indicate that electronic 
cigarettes might serve as a gateway for the use of 
conventional cigarettes. Among factors contributing to 
the prevalence of e-cigarette use cited by young people 
is the exposure to robust advertis ing campaigns, tihe 
ability to customize devices, flavours, nicotine content, 
peer use, enjoyment, and curiosity.5·6 This prompted 
US authorities earlier th is year to limit the flavours that 
could be included in electronic solutions (e-solutions, 
e-l iquid, ore-ju ice). This was done to reduce the appeal 
that smoking flavoured e-cigarettes might have to 
younger users. 
A major influence contributing significantly to 
favourably change the perception towards e-cigarettes 
in t he general population but also in the medical 
community, was a 2014 study, which sought to estimate 
the harm o f nicotine-containing products throug h 
modelling techniques. It concluded that conventional 
smoking was 20 times more harmful than vaping 
e-cigarettes.7 The UK Public Health took this up and 
started advertising the use of e-cigarettes, which it said 
were "at least 95% less harmful than cigarettes". This 
study has been contested with claims that advances in 
technolog y allows bigger power generation resulting 
in more vapour production and exposure of the user 
and bystanders to more, possibly harmful chemicals, 
and the ever increasing variety of flavours made up of 
chemicals that might be considered safe to eat but with 
as yet unknown consequences when inhaled. Another 
advancement has been the development of p rotonated 
nicotine which allows higher concentrations of nicotine 
to be inhaled without causing throat irritation, with the 
consequence of higher addiction to nicotine .8 
With the current understanding, should smokers 
be encouraged to change to vaping to improve their 
health? Unfortunately, there are different thoughts 
on this. A study in 2017 followed vapers who smoked 
e-cigarettes exclusively for 3.5 years and found no 
detriment to their health, even when investigated 
e xtensively. The study does high light that 3.5 
years is a short period of time to follow up 
for possible harm.9 The World Health 
Organizat ion remains uncommitted as 
to whether e -cigarettes should be 
advocated, neither as a means 
of smoking cessation nor as a 
means of harm reduction.'0 
As to second-hand 




and that by conventional ones, indicate that the latter 
generate more particles and stay around for longer 
periods of time.11 Yet it is well known that the belief that 
e ·cigarettes generate only a water vapour is certainly a 
misconception. Studies indicate particles in e-cigarette 
generated vapour to be cancerogenic, harmful to the 
unborn and a source of indoor pollution.12 
Of concern with the use of e-cigarettes has been 
the observation of a newly identified lung disease 
referred to as e-cigarette and vapour product use-
associated lung disease (EVALI). First noticed in early 
2017 in the US, some cases have also been reported in 
Europe. Patients complain of a cough, chest pain and 
shortness of breath. While some patients improve with 
no need for hospital care, others are not so lucky. By 
mid-January 2020, 2,668 hospitalized EVALI cases were 
reported in the US and nearly ha If the patie nts required 
intensive care to treat respiratory failure. Sixty died. 
Most patients were younger than 35 years old. While 
the exact cause of EVALI is still being investigated, it is 
well documented that all patients presenting with this 
condition had been vaping in the three months before 
getting sick. It has been confirmed that this condition 
is not an infective but rather an inflammatory process 
that causes lung injury. Of interest is the presence 
of tetrahydroca nnabinol (THC) which is the active 
ingredient in marijuana (cannabis), in up to 80% of 
e-solutions that had been used by patients presenting 
with th is condition. In up to half of the implicated 
e-solutions, another component found was vitamin E 
acetate (VEA). This is an additive that started being 
used in e·solutions as a cutting agent to thicken the 
solution. While VEA is considered safe to eat, it seems 
that its safety profile significantly changes when inhaled 
as a vapour. In such a scenario the Food and Drug 
Administration (FDA) in the US could only strongly 
advisee-cigarette users to avoid use of vaping products 
that were spiked with THC and to buy e-solutions only 
from reliable sources. It seems vapers are heeding 
this advice as new cases of EVALI have dropped since 
October 2019.13·" 
A new challenge with the ever-increasing number 
of vapers, is the further risk that comes with spiking of 
e-solutions with dangerous drugs of abuse. 
Of concern is the presence of psychedelic substances 
and opioids such as fentanyl (at least 50 times stronger 
than heroin) in e-solutions. While not yet a w idespread 
problem, it is envisaged that this new mode of drug 
administration could present itself as a new challenge to 
services caring for people who use drugs.1' It is important 
that users of e·cigarettes are made aware of the dangers 
involved when buying e-solutions from sources that are 
not certified as required by The Manufacture, Presentation 
and Sale of Tobacco and Related Products Regulations 
(S.L. 315.1 0), enacted under the Tobacco (Smoking 
Control) Act (Cap. 315). The aforementioned Regulations 
stipulate that electronic cigarettes are subject to a number 
of safeguards (e.g. maximum concentration of nicotine of 
20 mg/ml, maximum single use cartridge size of 2 ml) and 
requirements (e.g. notification to the compet ent authority 
prior to placing on the market, reporting of ingredients, 
inclusion of an information leaflet, and specific rules 
on advertising). 
Vapers who intentionally want to use drugs of abuse 
administered by uti lizing an e-cigarette, should be 
aware of the dangers involved and ensure safer use by 
following harm reduction guidelines such as starting off 
with lower doses, not mixing drugs and avoid as much 
as possible use of such substances when on t heir own. 
Help to address one's drug use is available. Sedqa may be 
contacted on helpline 179, 24 hours a day and 2388 51 10 
during office hours. 
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